VNDA is trading at cash level and estimates for Fanapt sales is valued too 0 by the market.
1y $149,4M Fanapt forecast sales
http://chart.ly/xfkw8q
High Short interest has direct correlation to price at settlement date. Shows SI is only factor to slide.
http://chart.ly/wnq3e9
59.40% (2010) 165.40% (2011)
EPS 2015 $5 estimates
Trading today below $7
| Price | 4.18 |
| Price Change Today | -$0.02 (-0.48%) |
| P&P rating |  |
| Zacks Rank | 4 - SELL |
| Open Price | $4.24 |
| Previous Close | $4.20 |
| Daily Range | $4.17 - $4.24 |
| 52-Week Range | $3.98 - $7.80 |
| Volume | 50,445 |
| Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. | |
1y $149,4M Fanapt forecast sales
http://chart.ly/xfkw8q
High Short interest has direct correlation to price at settlement date. Shows SI is only factor to slide.
http://chart.ly/wnq3e9
59.40% (2010) 165.40% (2011)
EPS 2015 $5 estimates
Trading today below $7
Comments: 275 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment